• Login
    • Login
    Advanced Search
    View Item 
    •   Maseno IR Home
    • Journal Articles
    • School of Public health & Community Development
    • Department of Biomedical Sciences
    • View Item
    •   Maseno IR Home
    • Journal Articles
    • School of Public health & Community Development
    • Department of Biomedical Sciences
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Investigating treatment response of patients with confirmed drug-resistant tuberculosis in an hiv-1-endemic population in western Kenya

    Thumbnail
    View/Open
    A21.2.full.pdf (61.83Kb)
    Publication Date
    2019
    Author
    Clement Shiluli, Collins Ouma, Jeremiah Khayumbi, Wilfred Murithi, Albert Ochieng, Susan Musau
    Metadata
    Show full item record
    Abstract/Overview
    In 2015, 10.4 million people worldwide had tuberculosis (TB) and 1.4 million deaths occurred, 400 000 of whom were HIV-positive. Sub-Saharan Africa accounted for 81% of these cases. In western Kenya, current data on the distribution of rifampicin (RIF) and isoniazid (INH) mutations is not available. The association of gene mutations with HIVinfection and the treatment response of HIV-infected and -uninfected patients with TB are not known. This study determined the proportion of drug-resistant Mycobacterium tuberculosis in sputum isolates and investigated the association of RIF and INH gene mutations with HIV status and monitored the treatment response of TB/HIV-co-infected patients.
    Permalink
    https://repository.maseno.ac.ke/handle/123456789/4898
    Collections
    • Department of Biomedical Sciences [95]

    Maseno University. All rights reserved | Copyright © 2022 
    Contact Us | Send Feedback

     

     

    Browse

    All of Maseno IRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Maseno University. All rights reserved | Copyright © 2022 
    Contact Us | Send Feedback